Pfizer: planned merger with Mylan confirmed
(CercleFinance.com) - Alongside the publication of its quarterly results, the generic-drug maker Mylan has announced an agreement to merge with Upjohn, Pfizer's off-patent drug business, by a transaction in shares alone.
Under the agreed terms, the new entity would be 43%-owned by Mylan's current shareholders and 57%-owned by Pfizer shareholders. Its would have pro-forma revenues of 19 billion to 20 billion dollars in 2020, as well as adjusted EBITDA of 7.5 billion to 8 billion dollars.
"The transaction will allow the new company to meaningfully expand the geographic reach of Mylan's existing broad product portfolio and future pipeline."
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Under the agreed terms, the new entity would be 43%-owned by Mylan's current shareholders and 57%-owned by Pfizer shareholders. Its would have pro-forma revenues of 19 billion to 20 billion dollars in 2020, as well as adjusted EBITDA of 7.5 billion to 8 billion dollars.
"The transaction will allow the new company to meaningfully expand the geographic reach of Mylan's existing broad product portfolio and future pipeline."
Copyright (c) 2019 CercleFinance.com. All rights reserved.